A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

Clinical Pharmacology and Therapeutics - United States
doi 10.1038/clpt.2009.217
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Furegrelate, a Thromboxane Synthase Inhibitor, Blunts the Development of Pulmonary Arterial Hypertension in Neonatal Piglets

Pulmonary Circulation
PulmonaryRespiratory Medicine
2012English

Incidence of Pulmonary Arterial Hypertension in Patients With Psoriasis: A Retrospective Cohort Study

Permanente journal,The
Medicine
2017English

Platelet Indices in Patients With Pulmonary Arterial Hypertension

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2011English

Pulmonary Arterial Hypertension in Patients Treated With Interferon

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2014English

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

Nasal Decongestant Exposure in Patients With Pulmonary Arterial Hypertension: A Pilot Study: TABLE 1

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2015English

Pulmonary Arterial Hypertension in Patients With Primary Sjögren’s Syndrome

Autoimmune Diseases
AllergyImmunologyMicrobiology
2014English

Acute Effects of Rho-Kinase Inhibitor Fasudil on Pulmonary Arterial Hypertension in Patients With Congenital Heart Defects

Circulation Journal
MedicineCardiovascular MedicineCardiology
2015English

The Trajectory to Diagnosis With Pulmonary Arterial Hypertension: A Qualitative Study

BMJ Open
Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy